CA
NZ
UK
AU
IND
US
Optical networking specialist Ciena is seeing strong tailwinds from the expanding need for AI‑related infrastructure. Its recent fiscal second‑quarter results and the upgraded long‑term revenue guidance point to a sustained growth path, echoing broader trends as cloud providers and large enterprises increase spending on …
Intel Corp. (NASDAQ: INTC) has announced a €5 billion ($5.7 billion) investment to expand its semiconductor campus in Leixlip, Ireland, as part of its strategy to strengthen its position in artificial intelligence and high-performance computing. The expansion aims to enhance production capabilities for processors …
IQSTEL Inc (NASDAQ: IQST) has completed a corporate realignment designed to refine its subsidiary structure. The company stated the move is intended to support operational efficiency while maintaining continuity in its core business activities. Leadership and financial reporting remain unaffected by the changes.
TACTI-004 was designed to evaluate eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy in a larger, pivotal-stage NSCLC population, building on encouraging earlier-stage data for the drug. The trial's discontinuation followed disappointing results, but the nature of those results — specifically a suppressed …
The $1.00 minimum bid price rule is one of Nasdaq's core continued-listing standards, designed to ensure that companies trading on the exchange maintain a share price reflecting a baseline level of market confidence and liquidity. Companies that fall below this threshold for an extended …
Axon Enterprise (NASDAQ: AXON) has strengthened its leadership team with two new independent directors. The appointments of Vivek Mohindra and Eiso Kant became effective on July 8, 2026, addressing existing vacancies on the board. Both directors will serve until the company’s 2027 annual stockholder …
Q32 Bio (NASDAQ: QTTB) posted Phase 2a SIGNAL-AA Part B results for bempikibart in severe alopecia areata, showing a 35.3% mean reduction in SALT scores in the mITT population and a 40% SALT-20 response rate. With no new safety signals emerging, the company said …
ROBBIN1 is a registration-directed study evaluating a neoadjuvant combination of BOT (botensilimab) and BAL (balstilimab) in patients with microsatellite-stable (MSS) colon cancer, a genetic subtype that has historically responded poorly to immunotherapy. Neoadjuvant treatment means the combination is given before surgery, with the goal …
Late-line metastatic cancer studies, by their nature, treat patients whose disease has progressed after multiple prior lines of therapy. These settings are notoriously difficult for demonstrating strong efficacy signals, both because the patient population is more heavily pretreated and because meaningful survival benefits are …
Chief Medical Officers play a central role in clinical-stage biotech companies, typically overseeing trial design, regulatory strategy, and the medical and scientific narrative the company presents to investors, physicians, and agencies like the FDA. A CMO departure ahead of major trial milestones can introduce …
Please wait processing your request...